Michelle Hammer speaks on a Panel at Bristol Meyers Squibb

Michelle spoke on a panel at Bristol Meyers Squibb as the patient advocate at the launch of the new schizophrenia medication COBENFY.

Cobenfy™ is a newly approved medication for the treatment of schizophrenia in adults. Unlike traditional antipsychotics, which target dopamine receptors, Cobenfy combines xanomeline and trospium chloride to act on cholinergic receptors, representing a novel mechanism in managing schizophrenia. This drug has shown promise in reducing symptoms such as hallucinations and disorganized thinking, based on studies measuring changes in the Positive and Negative Syndrome Scale (PANSS).

For those exploring new treatment options for schizophrenia, Cobenfy may represent a significant advancement, though careful medical supervision is essential to mitigate potential risks.

Remember to discuss with your doctor if Cobenfy is right for you.